BioSpace News Archive

Portage Biotech Inc. today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021. H.C. Wainwright 23rd Annual Global Investor Conference Date: September 13, 2021

Amolyt Pharmatoday announced that it will host a key opinion leader (KOL) webinar on AZP-3601, the Company’s lead product candidate for the potential treatment of hypoparathyroidism, on Friday, October 1, 2021 at 10:00 am ET.

Thermo Fisher Scientific today announced the Japan Ministry of Health, Labour and Welfare (MHLW), Japan’s regulatory agency, has granted approval for the Oncomine Dx Target Test as a next-generation sequencing (NGS)-based companion diagnostic (CDx) for patients with RET-fusion positive non-small-cell lung cancer (NSCLC)

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will host a key opinion leader (“KOL”) webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET.

Annovis Bio, Inc. (NYSE American: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22.

ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to improve patient health, today announced a poster presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting,

Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI® (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinson’s disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson’s disease at the International Parkinson and Movement Disorder Society’s (MDS) Virtual Congress 2021 being held September 17–22, 2021.